Truvian raises $105M, plans to submit benchtop blood-testing tech to FDA
Benchtop blood testing startup Truvian raised $105 million in series C funding, which it plans to use to pave the way to submit its device for FDA clearance.
Shares0
Truvian Sciences plans to seek FDA clearance and CLIA certification for its benchtop blood testing device. Photo credit: Truvian Sciences
Truvian Sciences, a startup building a benchtop blood analyzer, raised $105 million in funding.
The San Diego-based company plans to use the funds to seek 510(k) clearance and a CLIA waiver from the Food and Drug Administration, with plans to make its first regulatory submission before the end of the year. The company will also look to double its 87-person team, including its recent hire of Jay Srinivasan, former vice president of automation and informatics at Abbott.
Stamford Health has partnered with city and state officials and community organizations to execute its Covid-19 vaccine administration plans. The health system has ambitious plans to vaccinate 3,000 people a day, with a focus on health equity.
According to an analysis of 1.8 million medical claims, employers’ claims were down 4% in 2020. Although telehealth visits plateaued at the end of the year, they made up nearly 1 in 5 visits.
MedCity News
Confronting disparities in access to healthcare for underserved populations in 2021
Particularly at the point of care, we have the means and resources to directly inform, educate and offer service to those who have been marginalized across multiple demographic intersections of race, ethnicity and income.
Shares1
The global coronavirus pandemic is only the latest in decades of healthcare devastation for BIPOC communities: more illness, less care, more death. Many illnesses disproportionately affect certain populations due to disparities in healthcare access, but the pandemic helped shine a light on racism as a public health issue that needs to be broadly addressed. In 2021 and beyond, our government and health systems will need to make major shifts to address health inequality among ethnic groups, minorities and low-income populations.
Matt McNally
Throughout his career, Matt McNally has guided brands to maximize their impact through periods of rapidly changing audience behavior. He has successfully helped clients shift their approach to media from simply a planning and buying space to a strategic function that leverages new methods of communication and technology. Now as Chief Executive Officer of Outcome Health, he s doing the same thing for the point of care channel. He has been honored repeatedly as one of the most influential people in the life sciences industry, and, in 2019, was named to the “Health Influencer 50” by PR Week and MM&M.